Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer

References

• Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: where are we now? World J. Gastroenterol. 2018;24(20):2137–16. doi:10.3748/wjg.v24.i20.2137.
   PubMed Web of Science ®Google Scholar
• Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones M, Walker M, Bonilla CM, Wood BJ, Citrin DE, Gil Ramirez EM, et al. Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res clincanres. 2020;3624:2019. doi:10.1158/1078-0432.ccr-19-3624.
   Google Scholar
• O’Reilly EM, Oh DY, Dhani N, Renouf DJ, Ah Lee M, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, et al. Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(10):1431–1438. doi:10.1001/jamaoncol.2019.1588.
   PubMed Web of Science ®Google Scholar
• Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, and Cesano A. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018;6(1):1–17. doi:10.1186/s40425-018-0367-1.
   PubMed Web of Science ®Google Scholar
• Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al. Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation. Cancer Immunol. Res. 2014;2(7):616–631. doi:10.1158/2326-6066.CIR-14-0027.
   PubMed Web of Science ®Google Scholar
• Thorsson VV, Gibbs DL, Brown SD, wolfe D, Bortone DS, Ou Yang TH, Porta-Padro E, Gao GF, Plaisier CL, Eddy JA, et al. The Immune Landscape of Cancer. Immunity. 2018;48:812–830.e14.
   PubMed Web of Science ®Google Scholar
• Carstens JL, de Sampaio PC, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, and Kalluri R. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8(15095). doi:10.1038/ncomms15095.
   PubMedGoogle Scholar
• Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019;51(2):202–206. doi:10.1038/s41588-018-0312-8.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):S12–S16. doi:10.1038/nature24462.
   Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Mera M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, and Dieu-Nosjean MC. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:1–11. doi:10.3389/fimmu.2016.00407.
   PubMed Web of Science ®Google Scholar
• Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 2018;78(5):1308–1321. doi:10.1158/0008-5472.CAN-17-1987.
   PubMed Web of Science ®Google Scholar
• Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 2016;22(12):3005–3015. doi:10.1158/1078-0432.CCR-15-2762.
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35(11):571–580. doi:10.1016/j.it.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, and Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015;112(11):1782–1790. doi:10.1038/bjc.2015.145.
   PubMed Web of Science ®Google Scholar
• Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht Et, Katsahian S, Bizouard G, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 2014;189(7):832–844. doi:10.1164/rccm.201309-1611OC.
   PubMed Web of Science ®Google Scholar
• Cabrita R, Laus M, Sanna A, Donia M, Larsen MS, Mitra S, Johansson I, Phung B, Harbst K , Vallon-Christersson J, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–565. doi:10.1038/s41586-019-1914-8.
   PubMed Web of Science ®Google Scholar
• Petitprez F, de Reynies A, Keung EZ, Wei-Wu Chen T, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, et al. B cells are associated to sarcoma survival and immunotherapy response. Nature. 2020;577(7791):556–560. doi:10.1038/s41586-019-1906-8.
   PubMed Web of Science ®Google Scholar
• Helmink B, Reddy SM, Gao J, Zhang S, basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–555. doi:10.1038/s41586-019-1922-8.
   PubMed Web of Science ®Google Scholar
• Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. 2020;26(12):1845–1851. doi:10.1038/s41591-020-1086-y.
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012;9(5):e1001216. doi:10.1371/journal.pmed.1001216.
   PubMed Web of Science ®Google Scholar
• Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffel B, Gorjestani S, Liudahl SM, Truitt M, Olson P, et al. Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 2016;6(3):270–285. doi:10.1158/2159-8290.CD-15-0827.
   PubMed Web of Science ®Google Scholar
• Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 2017;7(1):1–7. doi:10.1038/s41598-017-17204-5.
   PubMed Web of Science ®Google Scholar
• Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;1–12. doi:10.1016/S0140-6736(18)30789-X.
   PubMed Web of Science ®Google Scholar
• Metsalu T, ClustVis: VJ. A web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566–W570. doi:10.1093/nar/gkv468.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillete MA, Pzaulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, and Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1.
   PubMed Web of Science ®Google Scholar
• H. L Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. (2013).
   Google Scholar
• Cibulskis K, Lawrence MS, Scarter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, and Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013;31(3):213–219. doi:10.1038/nbt.2514.
   PubMed Web of Science ®Google Scholar
• Larson DE, Harris CC, Chen K, Koboldt DC, Abbot TE, Dooling D, Ley TJ, Mardis ER, Wilson RK and Ding L. Somaticsniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28(3):311–317. doi:10.1093/bioinformatics/btr665.
   PubMed Web of Science ®Google Scholar
• Saunders CT, Wong WSW, Swamy S, Becq J, Murray LJ, and Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28(14):1811–1817. doi:10.1093/bioinformatics/bts271.
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, and Wilson RK.VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568–576. doi:10.1101/gr.129684.111.
   PubMed Web of Science ®Google Scholar
• Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, and Nielsen M. NetMHCpan-4.0: improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. J Immunol. 2017;199(9):3360–3368. doi:10.4049/jimmunol.1700893.
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Wang J, Fu J, Li T, Zheng X, Wang B, Gu S, Jiang P, Fan J, et al. Landscape of B cell immunity and related immune evaision in human cancer. Nat. Genet. 2019;51(3):560–567. doi:10.1038/s41588-018-0339-x.
   PubMed Web of Science ®Google Scholar
• Bolotin D, Poslavsky S, Davydov ANm, Frenkel FE, Fanchi L, Zolotareva OI, Hemmers S, Ptuintseva EV, Obraztsova AS, Shugay M, et al. Antigen receptor repertoire profiling from RNA-seq data. Nat. Biotechnol. 2017;35(10):908–911. doi:10.1038/nbt.3979.
   PubMed Web of Science ®Google Scholar
• Raphael BJ, The Cancer Genome Atlast Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185–203.e13.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BGE, Sumer SO, Aksoy BA, Jacobsen A, Byrne C, Heurer ML, Larsson E, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Sun R, Limkin EJ, Vakalopoulou M, Dercel L, Champiat S, Han SR, Verlingue Lo, Brandao D, Lancia A, Ammari S, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;2045:1–12.
   Google Scholar
• Castino GF, Cortese N, Capretti G, Serio S, Di Caro G, Mineri R, Margini E, Grizzi F, Cappello P, Novelli F, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology. 2016;5(4):1–14. doi:10.1080/2162402X.2015.1085147.
   Web of Science ®Google Scholar
• Vredevoogd DW, Kuilman T, Ligtenber MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, et al. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell. 2019;178(3):585–599.e15. doi:10.1016/j.cell.2019.06.014.
   PubMed Web of Science ®Google Scholar
• Braumüller H, Wieder T, Brenner E, Abmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494(7437):361–365. doi:10.1038/nature11824.
   PubMed Web of Science ®Google Scholar
• Bernard B, Rajamanickam V, Dubay C, Piening B, Alonso E, Jutric Z, Tang E, Newell P, Hansen P, Medler T, et al. Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer. PLoS One. 2020;15(8):1–19. doi:10.1371/journal.pone.0238380.
   Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermoot JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1). doi:10.1038/s41467-018-05072-0.
   PubMedGoogle Scholar
• Amsen D, Van Gisbergen KPJM, Hombrink P, Van Lier RAW. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol. 2018;19(6):538–546. doi:10.1038/s41590-018-0114-2.
   PubMed Web of Science ®Google Scholar
• Park SL, Buzzai A, Rautela J, Hor JL, Hockheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, et al. Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin. Nature. 2019;565(7739):366–371. doi:10.1038/s41586-018-0812-9.
   PubMed Web of Science ®Google Scholar
• Laidlaw BJ, Zhang N, Marshall HD, Staron MM, Guan T, Hu Y, Cauley LS, Craft J, and Kaech SM. CD4+ T Cell Help Guides Formation of CD103+ Lung-Resident Memory CD8+ T Cells during Influenza Viral Infection. Immunity. 2014;41(4):633–645. doi:10.1016/j.immuni.2014.09.007.
   PubMed Web of Science ®Google Scholar
• Mackay LK, Wynne-Jones E, Freestone D, Pellici DG, Mielke LA, Newman DM, Braun A, Masson F, Kallies A, Belz GT, et al. T-box Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate. Immunity. 2015;43(6):1101–1111. doi:10.1016/j.immuni.2015.11.008.
   PubMed Web of Science ®Google Scholar
• Workel HH, Lubbers JM, Arnold R, Prins TM, van der Vlies P, de Lange K, Bosse T, van Gool IC, Eggink FA, Wouters MCA, et al. A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol Res. 2019;7(5):787-796. doi: 10.1158/2326-6066.CIR-18-0517.
   PubMed Web of Science ®Google Scholar
• Lebien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112(5):1570–1580. doi:10.1182/blood-2008-02-078071.
   PubMed Web of Science ®Google Scholar
• De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 2015;15(3):137–148. doi:10.1038/nri3804.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramento J, Iglesias M, Sevillano M, Ibiza S, Canella A, Hernando-Momblona X, et al. TGF-beta drives immune evasion in genetically reconstituted colon cancer metastasis. Nat Publ Gr. 2018. doi:10.1038/nature25492.
   Google Scholar
• Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, and Tuveson D. Il1-induced Jak/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282–301. doi:10.1158/2159-8290.CD-18-0710.
   PubMed Web of Science ®Google Scholar
• Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9(4692). doi:10.1038/s41467-018-06654-8.
   Google Scholar
• Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A., Blair T, Whiteford M, O'Brien D, Ahmad R, et al. TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking. Nat. Commun. 2020;11(1):1–13. doi:10.1038/s41467-020-15404-8.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Diamond JM, Pilones KH, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, and Dermaria S. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75(11):2232–2242. doi:10.1158/0008-5472.CAN-14-3511.
   PubMed Web of Science ®Google Scholar
• Spranger S, Luke JS, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, and Gajewski TF. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl. Acad. Sci. U. S. A. 2016;113(48):E7759–E7768. doi:10.1073/pnas.1609376113.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Rosenberg SA. “Final common pathway” of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 2017;18(3):255–262. doi:10.1038/ni.3682.
   PubMed Web of Science ®Google Scholar
• Mesin L, Ersching J, Victora GD. Germinal Center B Cell Dynamics. Immunity. 2016;45(3):471–482. doi:10.1016/j.immuni.2016.09.001.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ji Z, Ngiow SF, Manne S, Cai Z, Huang AC, Johnson J, Staupe RP, Bengsch B, Xu C, et al. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. Immunity. 2019;51:840–855.e5. doi:10.1016/j.immuni.2019.09.013.
   PubMed Web of Science ®Google Scholar
• Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MH, Cardenas M, Wilikinson S, Lake R, Sowalsky AG, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465–470. doi:10.1038/s41586-019-1836-5.
   PubMed Web of Science ®Google Scholar
• Im SJ, Hashimoto M, Gerner MY, Lee Ju, Kissick HT, Burger MC, Shan Q, Hale JS,m Lee J, Nasti TH, et al. Defining CD8 + T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–421. doi:10.1038/nature19330.
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Chrristian E, Pawlak M, Dionne D, Xia J, Rozenblatt-Rosen, et al. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1 − CD8 + Tumor-Infiltrating T Cells. Immunity. 2019;50(181–194.e6):181–194.e6. doi:10.1016/j.immuni.2018.11.014.
   PubMed Web of Science ®Google Scholar
• Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, Klonowski KD, Lefrancois L, Cauley LS, Harmsen AG, Lund FE, et al. Persistence and Responsiveness of Immunologic Memory in the Absence of Secondary Lymphoid Organs. Immunity. 2006;25(4):643–654. doi:10.1016/j.immuni.2006.08.022.
   PubMed Web of Science ®Google Scholar
• Schrama D, thor Straten P, Fischer WH, McLellan AD, Brocker EB, Reisfel RA, and Becker JC. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity. 2001;14(2):111–121. doi:10.1016/S1074-7613(01)00094-2.
   PubMed Web of Science ®Google Scholar
• Hollern DP, Xu N, Thennavan A, Glodowski C, Garci-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, and Marron D. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell. 2019;179(1191–1206.e21):1191–1206.e21. doi:10.1016/j.cell.2019.10.028.
   PubMed Web of Science ®Google Scholar
• Tang ES, Newell PH, Wolf RF, Hansen PD, Cottam B, Ballesteros-Merino C, Gough MJ. Association of Immunologic Markers with Survival in Upfront Resectable Pancreatic Cancer. JAMA Surg. 2018;153(11):1055–1057. doi:10.1001/jamasurg.2018.1757.
   PubMed Web of Science ®Google Scholar
• Bruno TC, Ebner PJ, Moore BL, Squalls OG, Waugh KA, Eruslanov EB, Singhal S, Mitchell JD, Franklin WA, Merrick DT, et al. Antigen-Presenting Intratumoral B Cells Affect CD4+TIL Phenotypes in Non–Small Cell Lung Cancer Patients. Cancer Immunol. Res. 2017;5(canimm.0075.2017):898–907. doi:10.1158/2326-6066.CIR-17-0075.
   PubMed Web of Science ®Google Scholar
• Hulett TW, Jensen SM, Wilmarth PA, Reddy AP, Ballesteros-Merino C, Afentoulis ME, Dubay C, David LL, and Fox BA. Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer. 2018;6(1):1–14. doi:10.1186/s40425-018-0331-0.
   PubMed Web of Science ®Google Scholar
• Montfort A, Pearce O, Maniati E, Vincent BG, Bixby L, Bohm S, Dow T, Wilkes EH, Chakravarty P, Thompson R, et al. A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin. Cancer Res. 2017;23(1):250–262. doi:10.1158/1078-0432.CCR-16-0081.
   PubMed Web of Science ®Google Scholar
• Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat. Rev. Immunol. 2020;20(5):294–307. doi:10.1038/s41577-019-0257-x.
   PubMed Web of Science ®Google Scholar
• Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MKJ , Sondak VK, Weber JS, and Mule JJ. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: potential for Patient Selection for Immunotherapy? Sci Rep. 2012;2(765). doi:10.1038/srep00765.
   PubMedGoogle Scholar
• Colbeck EJ, Ager A, Gallimore A, Jones GW. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or Bystander Sentinels in disease? Front Immunol. 2017;8:1–18. doi:10.3389/fimmu.2017.01830.
   PubMed Web of Science ®Google Scholar
• Astorri E, Bombardieri M, Abba S, Peakman M, Pzzilli P, and Pitzalis C. Evolution of Ectopic Lymphoid Neogenesis and In Situ Autoantibody Production in Autoimmune Nonobese Diabetic Mice: cellular and Molecular Characterization of Tertiary Lymphoid Structures in Pancreatic Islets. J. Immunol. 2010;185(6):3359–3368. doi:10.4049/jimmunol.1001836.
   PubMed Web of Science ®Google Scholar
• Corsiero E, Delvecchio FR, Bombardieri M, Pitzalis C. B cells in the formation of tertiary lymphoid organs in autoimmunity, transplantation and tumorigenesis. Curr Opin Immunol. 2019;57:46–52. doi:10.1016/j.coi.2019.01.004.
   PubMed Web of Science ®Google Scholar
• Denton AE, Innocentin S, Carr EJ, Bradford BM, Lafouresse F, Mabbot NA, Morbe U, Ludewig B, Groom JR, Good-Jacobson KL, et al. Type I interferon induces CXCL13 to support ectopic germinal center formation. J. Exp. Med. 2019;216(3):621–637. doi:10.1084/jem.20181216.
   PubMed Web of Science ®Google Scholar
• Krautler NJ, Kana V, Kranich J, Tian Y, Perera D, Lemm D, Schwarz P, Armulik A, Browning JL, Tallquist MBush T, et al. Follicular dendritic cells emerge from ubiquitous perivascular precursors. Cell. 2012;150(1):194–206. doi:10.1016/j.cell.2012.05.032.
   PubMed Web of Science ®Google Scholar
• Gommerman JL, Browning JL, Ware CF. The Lymphotoxin Network: orchestrating a Type I interferon response to optimize adaptive immunity. Cytokine Growth Factor Rev. 2014;25(2):139–145. doi:10.1016/j.cytogfr.2014.02.002.
   PubMed Web of Science ®Google Scholar
• Young KH, Newell Pi, Cottam B, Friedman D, Savage T, Baird JR, Akporiaye E, Gough MJ, and Crittenden M. TGF Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models. Cancer Immunol. Res. 2014;2(10):1011–1022. doi:10.1158/2326-6066.CIR-13-0207.
   PubMed Web of Science ®Google Scholar
• Dominguez CX, Muller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, Breart B, Foreman O, Brainbridge TW, Castiglioni A, et al.Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov. 2020;10(2):232–253. doi:10.1158/2159-8290.CD-19-0644.
   PubMed Web of Science ®Google Scholar
• Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J, Stas M, Boon T, Coulie PG, and van Baren N. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012;72(16):3997–4007. doi:10.1158/0008-5472.CAN-12-1377.
   PubMed Web of Science ®Google Scholar
• Hannani D, Locher C, Yamazaki T, Coin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, et al. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ. 2014;21(1):50–58. doi:10.1038/cdd.2013.60.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008;8(1):34–47. doi:10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, and Reis e Sousa C. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018;172(5):1022–1037. doi:10.1016/j.cell.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Isaeva OI, Sharonov GV, Serebrovskaya EO, Turchaninova MA, Zaretsky AR, Shugay M, Chudakov DM. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes. Journal for ImmunoTherapy of Cancer. 2019;7(1):1–11. doi:10.1186/s40425-019-0747-1.
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2017;7(2):188–201. doi:10.1158/2159-8290.CD-16-1223.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16(2):121–126. doi:10.1038/nrc.2016.2.
   PubMed Web of Science ®Google Scholar